Actual Post Pandemic Strategies Are Inadequate To Assure Public Safety without VireXbuster® Spray
Frankfurt, Oct. 13th 2021: Fraunhofer Institut has tested VireXbuster is effective against Coronavirus (99.9%)
Frankfurt, 18. Nov. 2021: DaXem ist nun offizieller Lieferant der UNO
Frankfurt, Nov. 5th 2021: Daxem is now member of AMICI

News Dashboard

Nuremberg, 28-30 Mar. 2023

The United States is currently reassessing its pandemic response and updating infection control strategies. Experts believe that another pandemic is highly likely to occur in the next few decades, whether it is caused by a lab-leaked virus or arises naturally. Some COVID-19 experts estimate a 20% chance of experiencing an outbreak similar to the Omicron variant within the next two years.


Despite this potential future threat, the ongoing COVID-19 pandemic is not yet under control. Recent news of a significant COVID-19 surge in Okinawa, Japan, with cases 25 times higher than baseline and more severe than previous waves, raises concerns about what the United States may face in the coming months.


SARS-CoV-2, the virus causing COVID-19, is transitioning into an endemic phase in the United States, with a seroprevalence of over 96%. This does not mean the virus is eradicated through herd immunity, but rather that a more constant level of infections may persist. Long COVID continues to take a toll on society, with insufficient support for affected patients. A significant number of Americans have left the workforce due to long COVID, leading to substantial economic losses.


Given these circumstances, it is crucial to mitigate the spread of diseases and reduce the number of infections. Long COVID, for instance, only develops if one becomes infected with SARS-CoV-2.


Moreover, besides SARS-CoV-2, other diseases like methicillin-resistant Staphylococcus aureus (MRSA), and other antibiotic-resistant infections are on the rise. Screening plays a pivotal role in controlling these illnesses. Studies have shown the effectiveness of MRSA screening before surgery and hospital admission in preventing infections. The United Kingdom’s National Health Service (NHS) routinely performs hospital admission screening.


Data from the United States Veterans Health Administration (VHA) demonstrates that MRSA screening can significantly reduce hospital-onset infections in acute care settings. However, publicly available data regarding MRSA, COVID-19, and other pathogens in the United States are lacking. Making this data readily accessible to the public would promote awareness of current risks and help address the issue of multi-drug resistant organisms.


Unfortunately, current infectious disease policies seem to be lacking in addressing these problems and, in some cases, are retreating. Draft CDC Healthcare Infection Control Practices Advisory Committee (HICPAC) recommendations need to adequately address screening. Some proposed policies, such as Enhanced Barrier Precautions (EBP), have raised concerns, as they may not provide sufficient protection against transmission.


In summary, a proactive and data-driven approach to infection control, including comprehensive screening, is crucial to mitigate the impact of current and potential future pandemics and the rise of antibiotic-resistant infections.


In addition to the measures mentioned earlier, another effective tool in combating the transmission of viruses, bacteria, and fungi is VireXbuster Spray. VireXbuster Spray is an antimicrobial coating spray specially designed to create a protective barrier on surfaces. This innovative spray has demonstrated effectiveness against various pathogens, including viruses, bacteria, and fungi, making it a versatile solution for infection control.


Once applied, VireXbuster Spray forms a long-lasting protective shield on surfaces, capable of lasting for months. This durable coating actively combats the survival and spread of harmful microorganisms, providing an added layer of defense against infection.


With VireXbuster Spray, the risk of transmission through touch on infected surfaces can be significantly reduced. By inhibiting the survival and growth of pathogens on treated surfaces, the spray helps create a cleaner and safer environment, especially in high-traffic areas and shared spaces.


Including VireXbuster Spray in infection control strategies can complement other preventive measures, such as regular handwashing, proper hygiene practices, and social distancing. Together, these measures form a comprehensive approach to minimize the spread of infectious diseases, both in the current COVID-19 pandemic and potential future outbreaks.


By incorporating VireXbuster Spray into public spaces, workplaces, healthcare facilities, and homes, we can take proactive steps to protect ourselves and others from infections, providing greater peace of mind and contributing to the overall well-being of our communities.

Frankfurt, 28. Jan. 2022:

VireXbuster® Spray has today been certified by dermatest GmbH – a German-based Dermatology laboratory. The result has been tested as „excellent“.

VireXbuster Spray is from now dermatologically tested.

DaXem now approved UN supplier

Frankfurt, 18. Nov. 2021: DaXem GmbH, the producer of VireXbuster® Spray has been approved by the UN organization as supplier for antimicrobial and biocidal surface coatings.



DaXem now official member of AMiCI

Frankfurt, 5. November 2021: DaXem GmbH is now an official and accredited member of AMICI, the European Consortium active in the realm of development and promotion of new anti-microbial coatings. AMiCI stands for Anti-Microbial Coating Innovations, and has set out to prevent the spread of infectious diseases.

VireXbuster® is tested by the Fraunhofer Institute

Frankfurt, 13. Oktober  2021: VireXbuster® Spray, DaXem’s antimicrobial product, has been tested by the Fraunhofer Institute in Leipzig for the product’s efficacy against the Coronavirus, by 99,99 %.

VireXbuster® is tested by the QualityLab in Nuremberg

Frankfurt, 12. Sept. 2021: QualityLabs in Nuermberg has certified that VireXbuster® is particularly effective with regards to protecting our environment against bacteria. The certified efficacy is at 99.9%.